Pangenomic unit working on real-world evidence platform

Executive Summary

• Pangenomic Health’s wholly owned subsidiary, Mindleap Health, is developing a Real-World Evidence (RWE) platform specifically for the complementary and alternative medicine (CAM) market.
• The platform, named Mindleap RWE, aims to collect and analyze health data from diverse sources (clinical studies, historical use, modern evidence) using Large Language Models (LLMs) to support health claims and provide personalized product recommendations.
• The platform is expected to launch in the first quarter of 2026, with insights integrated into the NaraCare.AI platform and available via subscription to industry stakeholders.

Key Details

• Platform Name: Mindleap RWE Platform.
• Parent Company: Pangenomic Health Inc.
• Subsidiary: Mindleap Health Inc.
• Launch Timeline: First quarter of 2026.
• Core Functionality:
  • Collects and analyzes health data from traditional and non-traditional sources, including Western/non-Western clinical research, long-documented history of human use, and modern evidence.
  • Leverages leading Large Language Model (LLM) platforms to analyze datasets.
  • Aims to support an expanded interpretation of the "substantial evidence standard" (originally established by the FDA in 1962) for non-pharmaceutical health solutions.
• Integration and Use Cases:
  • Insights will be utilized within the NaraCare.AI platform to support personalized product recommendation functionality for consumers.
  • Data will be available on a subscription basis to manufacturers, distributors, retailers, researchers, and health practitioners.
• Related Assets:
  • NaraCare.AI: A platform for personalized health products leveraging insights from the Nara mental health app, Mindleap telehealth platform, and Mujn diagnostic tools.
  • Agenta Health: An e-commerce site serving as the springboard for the NaraCare.AI platform.
  • Mindleap Telehealth: Provides online access to wellness content and telehealth access to alternative health practitioners.
• Strategic Context: The company cites changes in the U.S. FDA and NIH under Robert F. Kennedy Jr. and decades-long WHO advocacy for CAM solutions as drivers for this opportunity to lower healthcare costs and improve global health outcomes.

Notable Quotes

• "With profound changes taking place in the U.S. Food and Drug Administration and National Institutes of Health by Robert F. Kennedy Jr., the Secretary of Health and Human Services, we believe there is a significant opportunity to develop a global evidence-based platform that collects information about the efficacy of non-pharmaceutical approaches to health and wellness," said Robert Nygren, executive chair of Pangenomic Health and newly appointed president of its wholly owned subsidiary, Mindleap Health.